Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESHAP and Y-90 Ibritumomab Tiuxetan in AIDS-Related NHL
NCT00310128Phase 2Withdrawn
- Sponsor
- AIDS Malignancy Consortium
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in AIDS-related lymphoma, sponsored by AIDS Malignancy Consortium. Planned start Feb 2006; status: withdrawn.
02
Drugs
ibritumomab tiuxetan
03
Conditions
AIDS-related lymphoma
Beyond the preview
Go deeper on NCT00310128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00310128.